Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2000-09-14
2004-02-17
Stucker, Jeffrey (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S279100, C424S283100, C530S826000
Reexamination Certificate
active
06692752
ABSTRACT:
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT Not Applicable
MICROFICHE APPENDIX
Not applicable
BACKGROUND OF THE INVENTION
Pathogens which cause sexually transmitted diseases (STDs) are known and there is an urgent need for effective vaccines to treat or prevent such conditions.
Sometimes sexually transmitted diseases are caused by one or more pathogens. Combination vaccines, able to prevent and/or treat, one or more STDs are therefore also required.
It has been found that certain vaccine formulations are surprisingly efficacious in preventing or treating STDs in female human subjects who are susceptible to or suffering from such STDs.
BRIEF SUMMARY OF THE INVENTION
The present invention relates to one or more antigens for the prevention or treatment of sexually transmitted diseases and the use thereof in the formulation of a vaccine, for administration to female human subjects, for the prevention or treatment of infections associated with pathogens which cause sexually transmitted diseases. The invention also relates to a method of administering the vaccine to females to prevent or treat infections associated with pathogens which cause sexually transmitted diseases.
REFERENCES:
patent: 4235877 (1980-11-01), Fullerton
patent: 4372945 (1983-02-01), Likhite
patent: 4474757 (1984-10-01), Arnon et al.
patent: 5057540 (1991-10-01), Kensil et al.
patent: 6027730 (2000-02-01), Francotte et al.
patent: 139417 (1984-08-01), None
patent: 00576478 (1994-01-01), None
patent: 0689454 (1994-03-01), None
patent: 2220211 (1990-01-01), None
patent: WO 92/03467 (1992-03-01), None
patent: WO 92/16231 (1992-10-01), None
patent: WO 93/02184 (1993-02-01), None
patent: WO 94/00152 (1994-01-01), None
patent: WO 94/00153 (1994-01-01), None
patent: WO 94/05792 (1994-03-01), None
patent: WO 94/20137 (1994-09-01), None
patent: WO 94/21292 (1994-09-01), None
patent: WO 95/17209 (1995-06-01), None
patent: WO 95/17210 (1995-06-01), None
patent: WO 96/02555 (1996-02-01), None
patent: WO 96/16231 (1996-05-01), None
patent: WO 96/19496 (1996-06-01), None
patent: WO 96/31618 (1996-10-01), None
patent: WO 96/33739 (1996-10-01), None
Straus et al. “Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes”, The Lancet, vol. 343 (Jun. 11, 1994), pp. 1460-1463.*
Cornellssen, et al., “The Transferrin Receptor Expressed by Gonococcal Strain FA1090 is Required for the Experimental Infection of Human Male Volunteers”,Molecular Microbiology,27(3): 611-616 (1998).
Washington, et al., “Chlamydia trachomatisInfections in the United States. What Are They Costing Us?”,JAMA,257(15): 2070-2072 (1987).
Grayston, et al., “New Knowledge of Chlamydiae and the Diseases They Cause”,The Journal of Infectious Diseases,132(1): 87-105 (1975).
Grayston, et al., “Importance of Reinfection in the Pathogenesis of Trachoma”,Reviews of Infectious Diseases,7(6): 717-725 (1985).
Morrison, et al., “Chlamydial Disease Pathogenesis. The 57-kD Chlamydial Hypersensitivity Antigen is a Stress Response Protein”,J. Exp. Med.,170: 1271-1283 (1989).
Blander, et al., “Mice Immunized with a Chlamydial Extract Have No Increase in Early Protecitve Immunity Despite Increased Inflammation Following Genital Infection by the Mouse Pneumonitis Agent ofChlamydial trachomatis”, Infection and Immunity,62(9): 3617-3624 (1994).
Wang, et al., “Immunotyping ofChlamydia trachomatiswith Monoclonal Antibodies”,The Journal of Infectious Diseases,152(4): 791-800 (1985).
Bavoil, et al., “Role of Disulfide Bonding in Outer Membrane Structure and Permeability inChlamydia trachomatis”, Infection and Immunity,44(2): 479-485 (1984).
Hatch, et al., “Synthesis of Disulfide-Bonded Outer Membrane Proteins During the Developmental Cycle ofChlamydia psittaciandChlamydia trachomatis”, Journal of Bacteriology,165(2): 379-385 (1986).
Stephens, et al., “Diversity ofChlamydia trachomatisMajor Outer Membrane Protein Genes”,Journal of Bacteriology,169(9): 3879-3885 (1987).
Yuan, et al., “Nucleotide and Deduced Amino Acid Sequences for the Four Variable Domains of the Major Outer Membrane Proteins of the 15Chlamydia trachomatisSerovars”,Infection and Immunity,57: 1040-1049 (1989).
Baehr, et al., “Mapping Antigenic Domains Expressed byChlamydia trachomatisMajor Outer Membrane Protein Genes”,Proc. Natl. Acad. Sci. USA,85: 4000-4004 (1988).
Lucero, et al., “Neutralization ofChlamydia trachomatisCell Culture Infection by Serovar-Specific Monoclonal Antibodies”,Infection and Immunity,50(2): 595-597 (1985).
Zhang, et al., “Protective Monoclonal Antibodies Recognize Epitopes Located on the Major Outer Membrane Protein ofChlamydia trachomatis”, The Journal of Immunology,138(2): 575-581 (1987).
Peterson, et al., “Protective Role of Magnesium in the Neutralization by Antibodies ofChlamydia trachomatisInfectivity”,Infection and Immunity,56(4): 885-891 (1988).
Zhang, et al., “Protective Monoclonal Antibodies toChlamydia trachomatisSerovar- and Serogroup-Specific Major Outer Membrane Protein Determinants”,Infection and Immunity,57(2): 636-638 (1989).
Allen, et al., “A Single Peptide from the Major Outer Membrane Protein ofChalmydia trachomatisElicits T Cell Help for the Production of Antibodies to Protective Determinants”,The Journal of Immunology,147(2): 674-679 (1991).
Su, et al., “Identification and Characterization of T Helper Cell Epitopes of the Major Outer Membrane Protein ofChlamydia trachomatis”, The Journal of Experimental Medicine,172: 203-212 (1990).
Manning, et al., Expression of the Major Outer Membrane Protein ofChlamydia trachomatis, Infection and Immunity,61(10): 4093-4098 (1993).
Koehler, et al., “Overexpression and Surface Localization of theChlamydia trachmatisMajor Outer Membrane Protein inEscherichia coli”, Molecular Microbiology,6(9): 1087-1094 (1992).
Pickett, et al., “High-Level Expression and Epitope Localization of the Major Outer Membrane Protein ofChlamydia trachomatisSerovar L1”,Molecular Microbiology,2(5): 681-685 (1988).
Taylor, et al., “Oral Immunization with Chlamydial Major Outer Membrane Protein (MOMP)”,Investigative Opthalmology&Visual Science,29(12): 1847-1853 (1988).
Batteiger, et al., “Partial Protection Against Genital Reinfection by Immunization of Guinea-Pigs with Isolated Outer-Membrane Proteins of the Chlamydial Agent of Guinea-Pig Inclusion Conjunctivitis”,Journal of General Microbiology,139: 2965-2972 (1993).
Tuffrey, et al., “Heterotypic Protection of Mice AgainstChlamydial Salpingitisand Colonization of the Lower Genital Tract with a Human Serovar F Isolate ofChlamydia trachomatisby Prior Immunization with Recombinant Serovar L1 Major Outer-Membrane Protein”,Journal of General Microbiology,138: 1707-1715 (1992).
Tuffrey, et al., “Salpingitisin Mice Induced by Human Strains ofChlamydia trachomatis”, Br. J. Exp. Path.,67: 605-616 (1986).
Tuffrey, et al., “Infertility in Mice Infected Genitally with a Human Strain ofChlamydia trachomatis”, J. Reprod. Fert.,78: 251-260 (1986).
Ramsey, et al., “Resolution of Chlamydial Genital Infection in B-Cell-Deficient Mice and Immunity to Reinfection”,Infection and Immunity,56(5): 1320-1325 (1988).
Rank, et al., “Chronic Chlamydial Genital Infection in Congenitally Athymic Nude Mice”,Infection and Immunity,48(3): 847-849 (1985).
Igietseme, et al., “Susceptibility to Reinfection After a Primary Chlamydial Genital Infection is Associated with a Decrease of Antigen-Specific T Cells in the Genital Tract”,Infection and Immunity,59(4): 1346-1351 (1991).
Igietseme, et al., “Resolution of Murine Chlamydial Genital Infection by the Adoptive Transfer of a Biovar-Specific, TH1 Lymphocyte Clone”,Regional Immunology,5(6): 317-324 (1993).
Igietseme, et al., “Role for CD8+ T Cells in Antichlamydial Immunity Defined by Chlamydia-Specific T-Lymphocyte Clones”,Infection and Immunity,62(11): 5195-5197 (1994).
Eisenberg, et al., “Comparative Structural Analysis of Glycoprotein gD of Herpes Simplex Virus Types 1 and 2”,J. Virol.,35: 428-435 (1980).
Cohen, et al., “Localization of Discontinuous Epitopes of Herpes Simplex Virus Glycopro
Slaoui Moncef Mohamed
Vandepapeliere Pierre G.
Kinzig Charles M.
Majarian William R.
SmithKline Beecham Biologicals (S.A.)
Stucker Jeffrey
Venetianer Steve
LandOfFree
Methods of treating human females susceptible to HSV infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating human females susceptible to HSV infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating human females susceptible to HSV infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3278983